1. Vollrath L. The Pineal Organ. Heidelberg: Springer-Verlag; 1981.

2. Collin JP. Differentiation and regression of the cfells of the sensory line in the epiphysis cerebri. In: Wolstenholme GEW, Knight, J., editor. The Pineal Gland. Edinburgh: Churchill Livingstone; 1972. p. 79-125.

3. Welsh MG. Pineal Calcification: Structural and Functional Aspects. Pineal Research Reviews 3:41-68, 1985.

4. Kappers JA. Innervation of the epiphysis cerebri in the albino rat. Anatomical Record 136:220-221, 1960.

5. Moller M. Introduction to mammalian pineal innervation. Microscopy Research Techniques 46:235-287, 1999.

6. Cassone VM, Natesan AK. Time and time again: the phylogeny of melatonin as a transducer of biological time. J Biol Rhythms 12:489-97, 1997.

7. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 3:350-61, 2003.

8. Klein DC, Coon SL, Roseboom PH, et al. The melatonin rhythm-generating enzyme: molecular regulation of serotonin N-acetyltransferase in the pineal gland. Recent Prog Horm Res 52:307-57; discussion 357-8, 1997.

9. Gastel JA, Roseboom PH, Rinaldi PA, et al. Melatonin production: proteasomal proteolysis in serotonin N-acetyltransferase regulation. Science 279:1358-60, 1998.

10. Bubenik GA. Localization, physiological significance and possible clinical implication of gastrointestinal melatonin. Biol Signals Recept 10:350-66, 2001.

11. Tosini G, Menaker M. Circadian rhythms in cultured mammalian retina. Science 272:419-21, 1996.

12. Arendt J. Melatonin and the Mammalian Pineal Gland. 1st ed. London: Chapman Hall; 1995.

13. Cavallo A, Ritschel WA. Pharmacokinetics of melatonin in human sexual maturation. J Clin Endocrinol Metab 81:1882-6, 1996.

14. Simonneaux V, Ribelayga C. Generation of the melatonin endocrine message in mammals: a review of the complex regulation of melatonin synthesis by norepinephrine, peptides, and other pineal transmitters. Pharmacol Rev 55:325-95, 2003.

15. Arendt J. Melatonin: characteristics, concerns, and prospects. J Biol Rhythms 20:291-303, 2005.

16 Middleton B, Arendt J, Stone BM. Human circadian rhythms in constant dim light (8 lux) with knowledge of clock time. J Sleep Res 5:69-76, 1996.

17. Czeisler CA, Duffy JF, Shanahan TL, et al. Stability, precision, and near-24-hour period of the human circadian pacemaker. Science 284:2177-81, 1999.

18. Moore RY, Klein DC. Visual pathways and the central neural control of a circadian rhythm in pineal serotonin N-acetyltransferase activity. Brain Res 71:17-33, 1974.

19. Cassone VM. Effects of melatonin on vertebrate circadian systems. Trends Neurosci 13:457-64, 1990.

20. Reiter RJ. Action spectra, dose-response relationships, and temporal aspects of light's effects on the pineal gland. Ann N Y Acad Sci 453:215-30, 1985.

21. Arendt J. Melatonin:characteristics, concerns and prospects. Journal of Biological Rhythms 20:291-303, 2005.

22. Lewy AJ, Wehr TA, Goodwin FK, et al. Light suppresses melatonin secretion in humans. Science 210:1267-9, 1980.

23. Bojkowski CJ, Aldhous ME, English J, et al. Suppression of nocturnal plasma melatonin and 6-sulphatoxymelatonin by bright and dim light in man. Horm Metab Res 19:437-40, 1987.

24. Boivin DB, Czeisler CA. Resetting of circadian melatonin and cortisol rhythms in humans by ordinary room light. Neuroreport 9:779-82, 1998.

25. Foster RG. Neurobiology: bright blue times. Nature 433:698-9, 2005.

26. Thapan K, Arendt J, Skene DJ. An action spectrum for melatonin suppression: evidence for a novel non-rod, non-cone photoreceptor system in humans. J Physiol 535:261-7, 2001.

27. Revell VL, Arendt J, Terman M, et al. Short-wavelength sensitivity of the human circadian system to phase-advancing light. J Biol Rhythms 20:270-2, 2005.

28. Rosenthal NE, Sack DA, Gillin JC, et al. Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiatry 41:72-80, 1984.

29. Wehr TA. The durations of human melatonin secretion and sleep respond to changes in daylength (photoperiod). J Clin Endocrinol Metab 73:1276-80, 1991.

30. Broadway J, Arendt J, Folkard S. Bright light phase shifts the human melatonin rhythm during the Antarctic winter. Neurosci Lett 79:185-9, 1987.

31. Illnerova H, Vanecek J. Entrainment of the rat pineal rhythm in melatonin production by light. Reprod Nutr Dev 28:515-26, 1988.

32. Wever RA. Light effects on human circadian rhythms: a review of recent Andechs experiments. J Biol Rhythms 4:161-85, 1989.

33. Zeitzer JM, Dijk DJ, Kronauer R, et al. Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression. J Physiol 526 Pt 3:695-702, 2000.

34. Revell VL, Arendt, J., Terman, M., Skene, D.J. Short wavelength sensitivity of the human circadian pacemaker to phase advancing light. in press:2004.

35. Lewy AJ, Newsome DA. Different types of melatonin circadian secretory rhythms in some blind subjects. J Clin Endocrinol Metab 56:1103-7, 1983.

36. Lockley SW, Skene DJ, Arendt J, et al. Relationship between melatonin rhythms and visual loss in the blind. J Clin Endocrinol Metab 82:3763-70, 1997.

37. Czeisler CA, Shanahan TL, Klerman EB, et al. Suppression of melatonin secretion in some blind patients by exposure to bright light. N Engl J Med 332:6-11, 1995.

38. Ebling FJ, Foster DL. Pineal melatonin rhythms and the timing of puberty in mammals. Experientia 45:946-54, 1989.

39. Arendt J. Role of the pineal gland and melatonin in seasonal reproductive function in mammals. Oxf Rev Reprod Biol 8:266-320, 1986.

40. Goldman BD. Mammalian photoperiodic system: formal properties and neuroendocrine mechanisms of photoperiodic time measurement. J Biol Rhythms 16:283-301, 2001.

41. Malpaux B, Migaud M, Tricoire H, et al. Biology of mammalian photoperiodism and the critical role of the pineal gland and melatonin. J Biol Rhythms 16:336-47, 2001.

42. Woodfill CJ, Wayne NL, Moenter SM, et al. Photoperiodic synchronization of a circannual reproductive rhythm in sheep: identification of season-specific time cues. Biol Reprod 50:965-76, 1994.

43. Weaver DR, Reppert SM. Maternal melatonin communicates daylength to the fetus in Djungarian hamsters. Endocrinology 119:2861-3, 1986.

44. Deveson S, Forsyth IA, Arendt J. Retardation of pubertal development by prenatal long days in goat kids born in autumn. J Reprod Fertil 95:629-37, 1992.

45. Davis FC. Melatonin: role in development. J Biol Rhythms 12:498-508, 1997.

46. Sizonenko PC, Lang U, Rivest RW, et al. The pineal and pubertal development. Ciba Found Symp 117:208-30, 1985.

47. Martin JE, Klein DC. Melatonin inhibition of the neonatal pituitary response to luteinizing hormone-releasing factor. Science 191:301-2, 1976.

48. Cassone VM. The pineal gland influences rat circadian activity rhythms in constant light. J Biol Rhythms 7:27-40, 1992.

49. Armstrong SM. Melatonin and circadian control in mammals. Experientia 45:932-8, 1989.

50. Deacon S, English J, Tate J, et al. Atenolol facilitates light-induced phase shifts in humans. Neurosci Lett 242:53-6, 1998.

51. Wirz-Justice A, Krauchi K, Cajochen C, et al. Evening melatonin and bright light administration induce additive phase shifts in dim light melatonin onset. J Pineal Res 36:192-4, 2004.

52. Badia P MB, Murphy P. Melatonin and thermoregulation. In: Reiter RJ YH, editor. Melatonin: Biosynthesis, Physiological Effects, and Clinical Applications. Boca Raton, FL: CRC Press; 1992.

53. Humlova M, Illnerova H. Melatonin entrains the circadian rhythm in the rat pineal N-acetyltransferase activity. Neuroendocrinology 52:196-9, 1990.

54. Reiter RJ. Melatonin and human reproduction. Ann Med 30:103-8, 1998.

55. Bosc MJ. Time of parturition in rats after melatonin administration or change of photoperiod. J Reprod Fertil 80:563-8, 1987.

56. Reppert SM, Weaver DR. Melatonin madness. Cell 83:1059-62, 1995.

57. Arendt J. Melatonin. Bmj 312:1242-3, 1996.

58. Vijayalaxmi, Thomas CR, Jr., Reiter RJ, et al. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 20:2575-601, 2002.

59. Marshall KA, Reiter RJ, Poeggeler B, et al. Evaluation of the antioxidant activity of melatonin in vitro. Free Radic Biol Med 21:307-15, 1996.

60. Gillette MU, McArthur AJ. Circadian actions of melatonin at the suprachiasmatic nucleus. Behav Brain Res 73:135-9, 1996.

61. Iuvone PM, Tosini G, Pozdeyev N, et al. Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. Prog Retin Eye Res 24:433-56, 2005.

62. Reiter RJ, Tan DX, Gitto E, et al. Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage. Pol J Pharmacol 56:159-70, 2004.

63. Blask DE, Dauchy RT, Sauer LA, et al. Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis 25:951-60, 2004.

64. Blask DE, Dauchy RT, Sauer LA. Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine 27:179-88, 2005.

65. Neuwelt EA, Lewy AJ. Disappearance of plasma melatonin after removal of a neoplastic pineal gland. N Engl J Med 308:1132-5, 1983.

66. Macchi MM, Bruce JA, Boulos Z, et al. Sleep, chronotype and seasonality after pineal resection in humans: initial findings. Society for Research on Biological Rhythms Abstracts 9:157, 2002.

67. Skene DJ, Vivien-Roels B, Sparks DL, et al. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease. Brain Res 528:170-4, 1990.

68. Stevens RG, Davis S, Thomas DB, et al. Electric power, pineal function, and the risk of breast cancer. Faseb J 6:853-60, 1992.

69. Blask DE, Dauchy RT, Sauer LA, et al. Light during darkness, melatonin suppression and cancer progression. Neuro Endocrinol Lett 23 Suppl 2:52-6, 2002.

70. Blask DE, Brainard GC, Dauchy RT, et al. Melatonin-depleted blood from premenopausal women exposed to light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 65:11174-84, 2005.

71. Akerstedt T, Froberg JE, Friberg Y, et al. Melatonin excretion, body temperature and subjective arousal during 64 hours of sleep deprivation. Psychoneuroendocrinology 4:219-25, 1979.

72. Strassman RJ, Qualls CR, Lisansky EJ, et al. Elevated rectal temperature produced by all-night bright light is reversed by melatonin infusion in men. J Appl Physiol 71:2178-82, 1991.

73. Cagnacci A, Elliott JA, Yen SS. Melatonin: a major regulator of the circadian rhythm of core temperature in humans. J Clin Endocrinol Metab 75:447-52, 1992.

74. Krauchi K, Cajochen C, Wirz-Justice A. A relationship between heat loss and sleepiness: effects of postural change and melatonin administration. J Appl Physiol 83:134-9, 1997.

75. Shochat T, Haimov I, Lavie P. Melatonin--the key to the gate of sleep. Ann Med 30:109-14, 1998.

76. Dijk DJ, Shanahan TL, Duffy JF, et al. Variation of electroencephalographic activity during non-rapid eye movement and rapid eye movement sleep with phase of circadian melatonin rhythm in humans. J Physiol 505 ( Pt 3):851-8, 1997.

77. Lockley SW, Skene DJ, Tabandeh H, et al. Relationship between napping and melatonin in the blind. J Biol Rhythms 12:16-25, 1997.

78. Kennaway DJ, Stamp GE, Goble FC. Development of melatonin production in infants and the impact of prematurity. J Clin Endocrinol Metab 75:367-9, 1992.

79. Waldhauser F, Weiszenbacher G, Frisch H, et al. Fall in nocturnal serum melatonin during prepuberty and pubescence. Lancet 1:362-5, 1984.

80. Waldhauser F, Boepple PA, Schemper M, et al. Serum melatonin in central precocious puberty is lower than in age-matched prepubertal children. J Clin Endocrinol Metab 73:793-6, 1991.

81. Berga SL, Mortola JF, Yen SS. Amplification of nocturnal melatonin secretion in women with functional hypothalamic amenorrhea. J Clin Endocrinol Metab 66:242-4, 1988.

82. Berga SL, Jones KL, Kaufmann S, et al. Nocturnal melatonin levels are unaltered by ovarian suppression in girls with central precocious puberty. Fertil Steril 52:936-41, 1989.

83. Arendt J, Labib MH, Bojkowski C, et al. Rapid decrease in melatonin production during successful treatment of delayed puberty. Lancet 1:1326, 1989.

84. Parry BL, Berga SL, Mostofi N, et al. Plasma melatonin circadian rhythms during the menstrual cycle and after light therapy in premenstrual dysphoric disorder and normal control subjects. J Biol Rhythms 12:47-64, 1997.

85. Scheer FA, Kalsbeek A, Buijs RM. Cardiovascular control by the suprachiasmatic nucleus: neural and neuroendocrine mechanisms in human and rat. Biol Chem 384:697-709, 2003.

86. O'Brien IA, Lewin IG, O'Hare JP, et al. Abnormal circadian rhythm of melatonin in diabetic autonomic neuropathy. Clin Endocrinol (Oxf) 24:359-64, 1986.

87. Yaprak M, Altun A, Vardar A, et al. Decreased nocturnal synthesis of melatonin in patients with coronary artery disease. Int J Cardiol 89:103-7, 2003.

88. Tapp E. The histology and pathology of the human pineal gland. Progress in Brain Research 52:481-500, 1979.

89. West RJ, Leonard JV. Familial insulin resistance with pineal hyperplasia: metabolic studies and effect of hypophysectomy. Arch Dis Child 55:619-21, 1980.

90. Sturner WQ, Lynch HJ, Deng MH, et al. Melatonin concentrations in the sudden infant death syndrome. Forensic Sci Int 45:171-80, 1990.

91. Axelrod L. Endocrine dysfunction in patients with tumours of the pineal region. In: Schmidek HH, editor. Pineal Tumours. New York: Masson Publishing; 1977. p. 61-77.

92. Wass JA, Jones AE, Rees LH, et al. hCG beta producing pineal choriocarcinoma. Clin Endocrinol (Oxf) 17:423-31, 1982.

93. Cohen AR, Wilson JA, Sadeghi-Nejad A. Gonadotropin-secreting pineal teratoma causing precocious puberty. Neurosurgery 28:597-602; discussion 602-3, 1991.

94. Horowitz MB, Hall WA. Central nervous system germinomas. A review. Arch Neurol 48:652-7, 1991.

95. Drummond KJ, Rosenfeld JV. Pineal region tumours in childhood. A 30-year experience. Childs Nerv Syst 15:119-26; discussion 127, 1999.

96. Jouvet A, Saint-Pierre G, Fauchon F, et al. Pineal parenchymal tumors: a correlation of histological features with prognosis in 66 cases. Brain Pathol 10:49-60, 2000.

97. Murata J, Sawamura Y, Ikeda J, et al. Twenty-four hour rhythm of melatonin in patients with a history of pineal and/or hypothalamo-neurohypophyseal germinoma. J Pineal Res 25:159-66, 1998.

98. Bartsch C, Bartsch H. Melatonin in cancer patients and in tumor-bearing animals. Adv Exp Med Biol 467:247-64, 1999.

99. Gilad E, Matzkin H, Zisapel N. Interplay between sex steroids and melatonin in regulation of human benign prostate epithelial cell growth. J Clin Endocrinol Metab 82:2535-41, 1997.

100. Megdal SP, Kroenke CH, Laden F, et al. Night work and breast cancer risk: A systematic review and meta-analysis. Eur J Cancer 2005.

101. Schernhammer ES, Hankinson SE. Urinary melatonin levels and breast cancer risk. J Natl Cancer Inst 97:1084-7, 2005.

102. Travis RC, Allen DS, Fentiman IS, et al. Melatonin and breast cancer: a prospective study. J Natl Cancer Inst 96:475-82, 2004.

103. Zhu Y BH, Zhang Y, Stevens RG, Zheng T. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev 14:268-270, 2005.

104. Archer SN, Robilliard DL, Skene DJ, et al. A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep 26:413-5, 2003.

105. Skene DJ, Bojkowski CJ, Currie JE, et al. 6-sulphatoxymelatonin production in breast cancer patients. J Pineal Res 8:269-76, 1990.

106. Arendt J. Melatonin: a new probe in psychiatric investigation? Br J Psychiatry 155:585-90, 1989.

107. Sack RL, Lewy AJ, White DM, et al. Morning vs evening light treatment for winter depression. Evidence that the therapeutic effects of light are mediated by circadian phase shifts. Arch Gen Psychiatry 47:343-51, 1990.

108. Lewy AJ, Sack RL, Miller LS, et al. Antidepressant and circadian phase-shifting effects of light. Science 235:352-4, 1987.

109. Terman M, Terman JS. Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects. CNS Spectr 10:647-63; quiz 672, 2005.

110. Mocaer E, Delalleau B, Boyer PA, et al. [Development of a new antidepressant : agomelatine]. Med Sci (Paris) 21:888-93, 2005.

111. Iguchi H, Kato KI, Ibayashi H. Melatonin serum levels and metabolic clearance rate in patients with liver cirrhosis. J Clin Endocrinol Metab 54:1025-7, 1982.

112. Arendt J. In what circumstances is melatonin a useful sleep therapy? Consensus statement, WFSRS focus group, Dresden, November 1999. J Sleep Res 9:397-8, 2000.

113. Arendt J, Skene D. Melatonin as a chronobiotic. Sleep Medicine Reviews 9:25-39, 2004.

114. Brzezinski A, Vangel MG, Wurtman RJ, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 9:41-50, 2005.

115. Arendt J, Stone, B., Skene, D.J. Jet lag and sleep disruption. In: Kryger M, Roth, T., Dement, W.C., editor. Principles and Practice of Sleep Medicine. 4th Edition ed. Philadelphia: WB Saunders and Co.; 2005.

116. Rajaratnam SM, Middleton B, Stone BM, et al. Melatonin advances the circadian timing of EEG sleep and directly facilitates sleep without altering its duration in extended sleep opportunities in humans. J Physiol 561:339-51, 2004.

117. Arendt J, Bojkowski C, Folkard S, et al. Some effects of melatonin and the control of its secretion in humans. Ciba Found Symp 117:266-83, 1985.

118. Lewy AJ, Bauer VK, Ahmed S, et al. The human phase response curve (PRC) to melatonin is about 12 hours out of phase with the PRC to light. Chronobiol Int 15:71-83, 1998.

119. Rajaratnam SM, Dijk DJ, Middleton B, et al. Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-hour production of reproductive hormones. J Clin Endocrinol Metab 88:4303-9, 2003.

120. Middleton B, Arendt J, Stone BM. Complex effects of melatonin on human circadian rhythms in constant dim light. J Biol Rhythms 12:467-77, 1997.

121. Lockley SW, Skene DJ, James K, et al. Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol 164:R1-6, 2000.

122. Sack RL, Brandes RW, Kendall AR, et al. Entrainment of free-running circadian rhythms by melatonin in blind people. N Engl J Med 343:1070-7, 2000.

123. Arendt J. Melatonin, circadian rhythms, and sleep. N Engl J Med 343:1114-6, 2000.

124. Arendt J, Skene DJ, Middleton B, et al. Efficacy of melatonin treatment in jet lag, shift work, and blindness. J Biol Rhythms 12:604-17, 1997.

125. Cagnacci A, Krauchi K, Wirz-Justice A, et al. Homeostatic versus circadian effects of melatonin on core body temperature in humans. J Biol Rhythms 12:509-17, 1997.

126. Cagnacci A, Elliott JA, Yen SS. Amplification of pulsatile LH secretion by exogenous melatonin in women. J Clin Endocrinol Metab 73:210-2, 1991.

127. Voordouw BC, Euser R, Verdonk RE, et al. Melatonin and melatonin-progestin combinations alter pituitary-ovarian function in women and can inhibit ovulation. J Clin Endocrinol Metab 74:108-17, 1992.

128. Luboshitzky R, Wagner O, Lavi S, et al. Abnormal melatonin secretion in male patients with hypogonadism. J Mol Neurosci 7:91-8, 1996.

129. Luboshitzky R, Wagner O, Lavi S, et al. Abnormal melatonin secretion in hypogonadal men: the effect of testosterone treatment. Clin Endocrinol (Oxf) 47:463-9, 1997.

130. Anderson RA, Lincoln GA, Wu FC. Melatonin potentiates testosterone-induced suppression of luteinizing hormone secretion in normal men. Hum Reprod 8:1819-22, 1993.

131. Waldhauser F, Lieberman HR, Lynch HJ, et al. A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, testosterone or cortisol. Neuroendocrinology 46:125-30, 1987.

132. Forsling ML, Williams AJ. The effect of exogenous melatonin on stimulated neurohypophysial hormone release in man. Clin Endocrinol (Oxf) 57:615-20, 2002.

133. Scheer FA, Van Montfrans GA, van Someren EJ, et al. Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 43:192-7, 2004.

134. Arendt J. Safety of melatonin in long-term use (?). J Biol Rhythms 12:673-81, 1997.

135. Guardiola-Lemaitre B. Toxicology of melatonin. J Biol Rhythms 12:697-706, 1997.

136. Suhner A, Schlagenhauf P, Johnson R, et al. Comparative study to determine the optimal melatonin dosage form for the alleviation of jet lag. Chronobiol Int 15:655-66, 1998.

137. Folkard S, Arendt J, Clark M. Can melatonin improve shift workers' tolerance of the night shift? Some preliminary findings. Chronobiol Int 10:315-20, 1993.

138. Burgess HJ, Sharkey KM, Eastman CI. Bright light, dark and melatonin can promote circadian adaptation in night shift workers. Sleep Med Rev 6:407-20, 2002.

139. Zhdanova IV, Wurtman RJ, Regan MM, et al. Melatonin treatment for age-related insomnia. J Clin Endocrinol Metab 86:4727-30, 2001.

140. Arendt J, Skene DJ. Melatonin as a chronobiotic. Sleep Med Rev 9:25-39, 2005.

141. Nagtegaal JE, Kerkhof GA, Smits MG, et al. Delayed sleep phase syndrome: A placebo-controlled cross-over study on the effects of melatonin administered five hours before the individual dim light melatonin onset. J Sleep Res 7:135-43, 1998.

142. Blask DE, Sauer LA, Dauchy RT. Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem 2:113-32, 2002.

143. Tamarkin L, Cohen M, Roselle D, et al. Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res 41:4432-6, 1981.

144. Lissoni P, Bolis S, Brivio F, et al. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies. Anticancer Res 20:2103-5, 2000.

145. Conti A, Maestroni GJ. The clinical neuroimmunotherapeutic role of melatonin in oncology. J Pineal Res 19:103-10, 1995.

146. Lissoni P, Chilelli M, Villa S, et al. Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res 35:12-5, 2003.

147. Morgan L, Hampton, S., Gibbs, M., Arendt, J. Circadian aspects of postprandial metabolism. Chronobiology International 20:795-808, 2003.

148. Knutsson A, Boggild H. Shiftwork and cardiovascular disease: review of disease mechanisms. Rev Environ Health 15:359-72, 2000.

149. Bittman EL. The sites and conseqences of melatonin binding in mammals. American Zoologist 33:200-211, 1993.

150. Vanecek J. Cellular mechanisms of melatonin action. Physiol Rev 78:687-721, 1998.

151. Vanecek J, Pavlik A, Illnerova H. Hypothalamic melatonin receptor sites revealed by autoradiography. Brain Res 435:359-62, 1987.

152. Williams LM, Morgan PJ. Demonstration of melatonin-binding sites on the pars tuberalis of the rat. J Endocrinol 119:R1-3, 1988.

153. Reppert SM, Weaver DR, Godson C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol Sci 17:100-2, 1996.

154. Lincoln GA, Clarke IJ. Photoperiodically-induced cycles in the secretion of prolactin in hypothalamo-pituitary disconnected rams: evidence for translation of the melatonin signal in the pituitary gland. J Neuroendocrinol 6:251-60, 1994.

155. Morgan PJ, King TP, Lawson W, et al. Ultrastructure of melatonin-responsive cells in the ovine pars tuberalis. Cell Tissue Res 263:529-34, 1991.

156. Williams LM, Martinoli MG, Titchener LT, et al. The ontogeny of central melatonin binding sites in the rat. Endocrinology 128:2083-90, 1991.

157. White BH, Sekura RD, Rollag MD. Pertussis toxin blocks melatonin-induced pigment aggregation in Xenopus dermal melanophores. J Comp Physiol [B] 157:153-9, 1987.

158. Barrett P, Morris M, Choi WS, et al. Melatonin receptors and signal transduction mechanisms. Biol Signals Recept 8:6-14, 1999.

159. Hazlerigg DG, Morgan PJ, Messager S. Decoding photoperiodic time and melatonin in mammals: what can we learn from the pars tuberalis? J Biol Rhythms 16:326-35, 2001.

160. Masana MI, Dubocovich ML. Melatonin receptor signaling: finding the path through the dark. Sci STKE 2001:PE39, 2001.

161. Carlberg C. Gene regulation by melatonin. Ann N Y Acad Sci 917:387-96, 2000.

162. Migaud M, Gavet S, Pelletier J. Partial cloning and polymorphism of the melatonin1a (Mel1a) receptor gene in two breeds of goat with different reproductive seasonality. Reproduction 124:59-64, 2002.

163. Ebisawa T, Uchiyama M, Kajimura N, et al. Genetic polymorphisms of human melatonin 1b receptor gene in circadian rhythm sleep disorders and controls. Neurosci Lett 280:29-32, 2000.

164. Reppert SM. Melatonin receptors: molecular biology of a new family of G protein-coupled receptors. J Biol Rhythms 12:528-31, 1997.

165. Zlotos DP. Recent advances in melatonin receptor ligands. Arch Pharm (Weinheim) 338:229-47, 2005.

166. Dubocovich ML, Masana MI, Iacob S, et al. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol 355:365-75, 1997.

167. Zee PC. Sleep promoting role of melatonin receptor agonists. Sleep 28:300-1, 2005.

168. Sumaya IC, Masana MI, Dubocovich ML. The antidepressant-like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT2 but not MT1 melatonin receptors. J Pineal Res 39:170-7, 2005.

169. Loiseau F, Le Bihan C, Hamon M, et al. Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats. Psychopharmacology (Berl) 182:24-32, 2005.

170. Yous S, Andrieux J, Howell HE, et al. Novel naphthalenic ligands with high affinity for the melatonin receptor. J Med Chem 35:1484-6, 1992.

171. Faust R, Garratt PJ, Jones R, et al. Mapping the melatonin receptor. 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2,1-a]indoles, 5,6-dihydroindolo[2,1-a]isoquinolines, and 6,7-dihydro-5H-benzo[c]azepino[2,1-a]indoles. J Med Chem 43:1050-61, 2000.

172. Redman JR, Francis AJ. Entrainment of rat circadian rhythms by the melatonin agonist S-20098 requires intact suprachiasmatic nuclei but not the pineal. J Biol Rhythms 13:39-51, 1998.

173. Krauchi K, Cajochen C, Mori D, et al. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 272:R1178-88, 1997.

174. Messager S, Ross AW, Barrett P, et al. Decoding photoperiodic time through Per1 and ICER gene amplitude. Proc Natl Acad Sci U S A 96:9938-43, 1999.

175. Johnston JD, Messager S, Barrett P, et al. Melatonin action in the pituitary: neuroendocrine synchronizer and developmental modulator? J Neuroendocrinol 15:405-8, 2003.

176. Lincoln G, Messager S, Andersson H, et al. Temporal expression of seven clock genes in the suprachiasmatic nucleus and the pars tuberalis of the sheep: evidence for an internal coincidence timer. Proc Natl Acad Sci U S A 99:13890-5, 2002.

177. Messager S, Hazlerigg DG, Mercer JG, et al. Photoperiod differentially regulates the expression of Per1 and ICER in the pars tuberalis and the suprachiasmatic nucleus of the Siberian hamster. Eur J Neurosci 12:2865-70, 2000.

178. Poirel VJ, Boggio V, Dardente H, et al. Contrary to other non-photic cues, acute melatonin injection does not induce immediate changes of clock gene mRNA expression in the rat suprachiasmatic nuclei. Neuroscience 120:745-55, 2003.

179. Lincoln GA, Andersson H, Loudon A. Clock genes in calendar cells as the basis of annual timekeeping in mammals--a unifying hypothesis. J Endocrinol 179:1-13, 2003.

180. von Gall C, Garabette ML, Kell CA, et al. Rhythmic gene expression in pituitary depends on heterologous sensitization by the neurohormone melatonin. Nat Neurosci 5:234-8, 2002.